MPM BioImpact’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

MPM BioImpact’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-234,478	Closed	-$23.9M	–	35
2023 Q2	$23.9M	Buy	234,478 +57,604	+33%	+$5.45M	4.81%	5
2023 Q1	$16.5M	Sell	176,874 -17,307	-9%	-$1.02M	4.3%	9
2022 Q4	$7.38M	Buy	194,181 +15,123	+8%	+$520K	1.91%	16
2022 Q3	$4.5M	Sell	179,058 -942	-0.5%	-$26.1K	1.07%	22
2022 Q2	$5.47M	Hold	180,000	–	–	1.52%	20
2022 Q1	$5.9M	Buy	+180,000	New	+$5.34M	1.58%	18

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MPM BioImpact's RETA Position: Q3 2023 in Review

MPM BioImpact sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 234,478 shares — an estimated $23.9M sold.

MPM BioImpact first reported a position in RETA in Q1 2022 and held it in 6 quarters. The position peaked at $23.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

MPM BioImpact reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
MPM BioImpact sold 234,478 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $23.9M.
MPM BioImpact first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 6 quarters.
MPM BioImpact's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $23.9M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on MPM BioImpact's 13F filing for Q3 2023, filed 14 Nov 2023.